Key Specifications Table
|CAS #||Empirical Formula|
|827022-32-2||C₂₄H₂₉N₇O₂ • HCl|
An invalid quantity was specified. The product quantity has been adjusted.
|5.30487.0001||Glass bottle||5 mg|
|Overview||A cell-permeable, orally available and brain permeant, non-toxic pyridopyrimidinone compound that acts as a potent, selective, reversible, ATP competitive inhibitor of Cdk4 and Cdk6 (IC50 = 11, 9, and 15 nM for Cdk4/D1, Cdk4/D3 and Cdk6/D2, respectively). Hence, it reduces retinoblastoma protein phosphorylation at Ser780/Ser795 (IC50 = 66 nM in MDA-435 cells) and arrests cell cycle at G1 phase. Acts as a cytostatic agent, but does induce apoptotic cell death when used alone. However, it potentiates the cytotoxicity of dexamethasone (Cat. No. 265005), bortezomib (Cat. No. 504314), and tamoxifen (Cat. No. 579000) in estrogen receptor (ER)-positive cell lines. Exhibits only a trivial inhibitory activity towards Cdk2/E2, Cdk2/A, Cdk1/B and Cdk5/p25 in a 36-kinase panel (IC50 > 10 µM). Improves endoderm differentiation of late G1-human embryonic stem cells expressing Smad2 or Smad3 (~ 750 nM) and further enhances endoderm differentiation into hepatic and pancreatic progenitor cells. Shown to regress the growth of human breast tumor xenografts in murine models (~150 mg/kg, p.o., daily).
Please note that the molecular weight for this compound is batch-specific due to variable water content.
|Synonyms||6-Acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, HCl, Cdk4/Cdk6 Inhibitor V, PD-0332991, HCl, PF-332991, HCl|
|Hill Formula||C₂₄H₂₉N₇O₂ • HCl|
|Chemical formula||C₂₄H₂₉N₇O₂ • HCl|
|Primary Target||Cdk4 & Cdk6|
|Purity||≥97% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
StemSelect® PD 0332991 - CAS 827022-32-2 - Calbiochem SDS
|Pauklin, S. and Vallier, L., 2013. Cell 155, 135.
Finn, R.S., et al. 2009. Breast Cancer Res. 11, R17.
Menu, E., et al. 2008. Cancer Res. 68, 5519.
Baughn, L.B., et al. 2006. Cancer Res. 66, 7661.
Fry, D.W., et al. 2004. Mol. Cancer Ther. 3, 1427.
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.